Spero Therapeutics SPRO

NASDAQ SPRO

$1.17 -0.02 (-1.68%)

At close: Sep 9, 2026 · 4:00 PM EDT

Key Stats

Market Cap67.82 Mn

P/E11.71

P/S1.44

Div. Yield0.00

Total Debt (Qtr)91,000.00

Add ratio to table…

About

Spero Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need. Since its inception in 2013 the company has concentrated its efforts and financial resources on acquiring and developing product and technology rights building its intellectual property portfolio and conducting research and development activities for its product candidates. The firm does not have…

Spero Therapeutics generates revenue primarily through license agreements milestone payments royalties and government grants. Under its agreement with GlaxoSmithKline the company received an upfront cash payment and is eligible to receive development sales and commercial milestones as well as low single digit to low double digit tiered royalties on net product sales. Additionally the company has entered into collaborations with Meiji Everest Pfizer and Vertex that provide milestone payments and potential royalties. Government awards from BARDA NIAID CARB-X SBIR and the Department of Defense also contribute to the company's revenue stream.

Within the biopharmaceutical industry Spero Therapeutics operates in a highly competitive environment that includes large pharmaceutical companies specialty biotechnology firms and generic drug manufacturers. Its primary competitive advantage lies in developing tebipenem HBr which if approved would be the first oral carbapenem for the treatment of complicated urinary tract infections. The drug benefits from a Qualified Infectious Disease Product designation and a fast track designation from the FDA which may accelerate review and provide regulatory exclusivity extensions. The partnership with GlaxoSmithKline provides access to substantial development and commercialization resources while allowing Spero to retain royalty interests.

Spero Therapeutics serves collaborators and partners rather than a traditional end user customer base. Key partners include GlaxoSmithKline with whom it licenses tebipenem HBr Meiji which holds rights in certain Asian territories Everest which has rights in Greater China South Korea and Southeast Asia Pfizer which previously held rights to SPR206 and Vertex which provided know how for SPR720. The company also receives funding from government agencies such as BARDA NIAID CARB-X SBIR and the Department of Defense.

Investment Thesis

▲ Bull case

The FDA approval of Utebzi (tebipenem pivoxil) represents a transformative milestone for Spero Therapeutics, positioning the company at the forefront of addressing the growing global threat of antimicrobial resistance with a first-in-class oral carbapenem antibiotic. This approval is not merely a regulatory win but a validation of over a decade of R&D investment, enabling Spero to transition from a clinical-stage biotech to a revenue-generating entity through its partnership with GSK. The drug’s unique value proposition—offering an effective oral alternative to intravenous carbapenems for complicated UTIs, including pyelonephritis—directly targets a massive unmet need: over 3 million annual cUTI cases in the U.S. alone, with treatment failure impacting up to 34% of patients and driving over $6 billion in annual healthcare costs. By enabling outpatient treatment, Utebzi has the potential to significantly reduce hospital burden, lower systemic costs, and improve patient quality of life, creating a strong foundation for rapid adoption among urologists and infectious disease specialists who are increasingly pressured to manage resistant infections outside inpatient settings. The non-inferiority results from the PIVOT-PO trial (58.5% success rate for tebipenem pivoxil vs. 60.2% for IV imipenem-cilastatin, with a confidence interval crossing zero) robustly support its clinical efficacy, while its favorable safety profile—limited to mild/moderate diarrhea and headache—enhances its real-world usability. Crucially, the Qualified Infectious Disease Product (QIDP) and Fast Track designations confer significant commercial advantages, including extended market exclusivity and priority review vouchers, which Spero can leverage to maximize returns from GSK’s global commercialization engine outside select Asian territories. This approval transforms Spero’s financial trajectory: while near-term revenue may be modest, the milestone payments and tiered royalties from GSK’s launch—anticipated by end-2026—will provide a non-dilutive cash flow stream that could fund further pipeline development or even attract acquisition interest, particularly as big pharma seeks de-risked anti-infective assets amid rising resistance threats. The market is underestimating the strategic inflection point this approval creates—Spero is no longer just a pipeline company but a validated innovator with a commercially viable product in hand, and the partnership with GSK provides scale and commercial expertise that Spero alone could never achieve, turning a scientific breakthrough into a tangible patient impact and shareholder value driver.

The FDA approval of Utebzi (tebipenem pivoxil) represents a transformative milestone for Spero Therapeutics, positioning the company at the forefront of addressing the growing global threat of antimicrobial resistance with a first-in-class oral carbapenem antibiotic. This approval is not merely a regulatory win but a validation of over a decade of R&D investment, enabling Spero to transition from a clinical-stage biotech to a revenue-generating entity through its partnership with GSK. The drug’s unique value proposition—offering an effective oral alternative to intravenous carbapenems for complicated UTIs, including pyelonephritis—directly targets a massive unmet need: over 3 million annual cUTI cases in the U.S. alone, with treatment failure impacting up to 34% of patients and driving over $6 billion in annual healthcare costs. By enabling outpatient treatment, Utebzi has the potential to significantly reduce hospital burden, lower systemic costs, and improve patient quality of life, creating a strong foundation for rapid adoption among urologists and infectious disease specialists who are increasingly pressured to manage resistant infections outside inpatient settings. The non-inferiority results from the PIVOT-PO trial (58.5% success rate for tebipenem pivoxil vs. 60.2% for IV imipenem-cilastatin, with a confidence interval crossing zero) robustly support its clinical efficacy, while its favorable safety profile—limited to mild/moderate diarrhea and headache—enhances its real-world usability. Crucially, the Qualified Infectious Disease Product (QIDP) and Fast Track designations confer significant commercial advantages, including extended market exclusivity and priority review vouchers, which Spero can leverage to maximize returns from GSK’s global commercialization engine outside select Asian territories. This approval transforms Spero’s financial trajectory: while near-term revenue may be modest, the milestone payments and tiered royalties from GSK’s launch—anticipated by end-2026—will provide a non-dilutive cash flow stream that could fund further pipeline development or even attract acquisition interest, particularly as big pharma seeks de-risked anti-infective assets amid rising resistance threats. The market is underestimating the strategic inflection point this approval creates—Spero is no longer just a pipeline company but a validated innovator with a commercially viable product in hand, and the partnership with GSK provides scale and commercial expertise that Spero alone could never achieve, turning a scientific breakthrough into a tangible patient impact and shareholder value driver.

▼ Bear case

Despite the FDA approval of Utebzi, Spero Therapeutics faces significant near-term financial and commercial risks that the market may be overlooking, particularly given its reliance on GSK for commercialization and the modest clinical efficacy demonstrated in the PIVOT-PO trial. While the approval is a scientific achievement, the drug’s overall success rate of 58.5%—only marginally below the comparator’s 60.2%—raises questions about its real-world effectiveness, especially in a crowded antibiotic landscape where physicians may hesitate to adopt a new agent with only non-inferiority data and no superiority signal, particularly when established IV carbapenems remain widely available and familiar. The anticipated launch timeline—end of 2026—creates a prolonged revenue gap, during which Spero must sustain operations with limited cash runway, relying solely on milestone payments that are likely back-loaded and contingent on GSK’s commercial execution, which has historically been inconsistent in anti-infectives compared to its vaccine or oncology franchises. Furthermore, the drug’s labeling restriction to patients with “limited or no alternative oral treatment options” severely constrains its addressable market, as many cUTI cases can still be managed with existing oral agents like fluoroquinolones or trimethoprim-sulfamethoxazole (despite resistance concerns), and clinicians may default to familiar alternatives rather than adopt a new, potentially costlier oral carbapenem without clear outcome advantages. The safety profile, while benign in trials, includes critical warnings for carnitine depletion and CNS seizures—risks that could deter use in vulnerable populations like the elderly or those with renal impairment, who are disproportionately affected by cUTIs, thereby limiting uptake. Additionally, the partnership structure, while beneficial for de-risking development, means Spero retains minimal control over pricing, promotion, or launch strategy; GSK’s prioritization of Utebzi within its broad anti-infectives portfolio is uncertain, especially given the company’s recent focus on vaccines and respiratory therapeutics, and any delay or tepid commercial effort by GSK could severely impair Spero’s royalty stream. Finally, the looming threat of generic competition—though delayed by QIDP exclusivity—remains a long-term concern, as the oral carbapenem class is scientifically replicable, and if resistance patterns shift or newer alternatives emerge, Utebzi’s commercial lifespan could be shorter than anticipated, leaving Spero with a single-product dependency and limited pipeline depth to fall back on, making its valuation highly sensitive to the success of this one asset in a niche, tightly regulated market.

Despite the FDA approval of Utebzi, Spero Therapeutics faces significant near-term financial and commercial risks that the market may be overlooking, particularly given its reliance on GSK for commercialization and the modest clinical efficacy demonstrated in the PIVOT-PO trial. While the approval is a scientific achievement, the drug’s overall success rate of 58.5%—only marginally below the comparator’s 60.2%—raises questions about its real-world effectiveness, especially in a crowded antibiotic landscape where physicians may hesitate to adopt a new agent with only non-inferiority data and no superiority signal, particularly when established IV carbapenems remain widely available and familiar. The anticipated launch timeline—end of 2026—creates a prolonged revenue gap, during which Spero must sustain operations with limited cash runway, relying solely on milestone payments that are likely back-loaded and contingent on GSK’s commercial execution, which has historically been inconsistent in anti-infectives compared to its vaccine or oncology franchises. Furthermore, the drug’s labeling restriction to patients with “limited or no alternative oral treatment options” severely constrains its addressable market, as many cUTI cases can still be managed with existing oral agents like fluoroquinolones or trimethoprim-sulfamethoxazole (despite resistance concerns), and clinicians may default to familiar alternatives rather than adopt a new, potentially costlier oral carbapenem without clear outcome advantages. The safety profile, while benign in trials, includes critical warnings for carnitine depletion and CNS seizures—risks that could deter use in vulnerable populations like the elderly or those with renal impairment, who are disproportionately affected by cUTIs, thereby limiting uptake. Additionally, the partnership structure, while beneficial for de-risking development, means Spero retains minimal control over pricing, promotion, or launch strategy; GSK’s prioritization of Utebzi within its broad anti-infectives portfolio is uncertain, especially given the company’s recent focus on vaccines and respiratory therapeutics, and any delay or tepid commercial effort by GSK could severely impair Spero’s royalty stream. Finally, the looming threat of generic competition—though delayed by QIDP exclusivity—remains a long-term concern, as the oral carbapenem class is scientifically replicable, and if resistance patterns shift or newer alternatives emerge, Utebzi’s commercial lifespan could be shorter than anticipated, leaving Spero with a single-product dependency and limited pipeline depth to fall back on, making its valuation highly sensitive to the success of this one asset in a niche, tightly regulated market.

Product and Service Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AMGN	Amgen Inc	primary	211.73 Bn	24.22	5.56	62.75 Bn
2	GILD	Gilead Sciences, Inc.	primary	180.92 Bn	-62.49	5.94	28.66 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	primary	132.16 Bn	30.00	10.50	-
4	REGN	Regeneron Pharmaceuticals, Inc.	primary	82.89 Bn	19.15	5.34	1.99 Bn
5	ARGX	Argenx Se	primary	61.41 Bn	35.80	11.75	-
6	MRNA	Moderna, Inc.	primary	53.99 Bn	-17.13	24.23	0.59 Bn
7	ALNY	Alnylam Pharmaceuticals, Inc.	primary	34.48 Bn	44.51	7.18	-
8	BIIB	Biogen Inc.	primary	31.15 Bn	37.32	3.11	8.09 Bn

Spero Therapeutics SPRO

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password